Clinical Trial Update: Everolimus and Imatinib Mesylate in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia Who Are Not in Complete Cytogenetic Remission After Previous Imatinib Mesylate [Phase 1, Phase 2]

View source ↗

Summary

A completed Phase 1/2 trial evaluating the combination of everolimus and imatinib mesylate in patients with chronic phase chronic myeloid leukemia who were not …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Myeloid Leukemia

Drugs mentioned

• Everolimus (everolimus)
• Imatinib mesylate (Imatinib)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Leukemia | Phase 1, Phase 2 | Status: COMPLETED